Dr. Mohit Narang, MD

Dr. Narang practices at Howard County Gastrointestinal Diagnostic Center in Columbia, Maryland.

Dr. Narang's NPI, 1881695351, was assigned on August 9, 2005. Dr. Narang holds Maryland license D67468.

Dr. Narang's primary practice is Howard County Gastrointestinal Diagnostic Center, at 10710 Charter Dr, Columbia, MD 21044 in Howard County. The practice phone is (410) 772-7345.

Dr. Narang's primary practice is Howard County Gastrointestinal Diagnostic Center in Columbia, Maryland. Dr. Narang is also affiliated with Johns Hopkins Howard County Medical Center. The medical group on file is Maryland Oncology Hematology. Dmand AI also links Dr. Narang to 1 more group practice or clinic, 1 home health agency and 1 hospice, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Narang practices, 4 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Narang's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Narang's licenses on file in 2 states: Maryland and Arkansas.

CMS data shows 194,651 Medicare services from Dr. Narang across 76 procedure codes in 2024, for 1,480 Medicare patients. Medicare paid $3,341,227 for them. Every service was in an office.

CMS counts 1,480 Medicare patients who saw Dr. Narang in 2024. The largest group is 75 to 84, with 635 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 8% are also on Medicaid. Their average risk score is 1.74, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Narang's median patient age at 65, with 52% women.

In 2024, Dr. Narang wrote 1,164 Medicare Part D claims for 207 patients. 60% of them were for generic drugs. CMS names the drug for 971 of them, across 27 drugs with 11 or more claims each, at $3,758,741 in total drug cost. In 2023, CMS named 559 claims across 20 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 91 out of 100 for Dr. Narang for performance year 2024, reported individually. Dr. Narang accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Narang as offering telehealth.

Dmand AI links 20 papers to Dr. Narang, published from 2014 to 2024. 2018 was the busiest year, with 3. The most frequent topics are Multiple Myeloma, Allografts and Antineoplastic Combined Chemotherapy Protocols. Dr. Narang has published most often in Clin Lymphoma Myeloma Leuk. Dr. Narang's most frequent co-authors are Rafat Abonour, MD, Kathleen Clare Toomey, MD and Howard R. Terebelo, DO.

Dmand AI links Dr. Narang to 5 clinical trials, 3 of them phase 2 studies. 2 are still active or recruiting. Conditions studied include Breast Neoplasms, Carcinoma, Non-Small-Cell Lung and Multiple Myeloma.

CMS Open Payments shows 1,949 general payments to Dr. Narang from 79 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 61% of the total. Janssen Pharmaceuticals, Inc paid the most, $304,779. It also lists 4 research payments totaling $17,007 from 2016 to 2019.